Acasti Pharma Inc – Class A (NASDAQ:ACST) Has Increase in Shorts

June 16, 2018 - By Marry Poplack

Acasti Pharma Inc. (NASDAQ:ACST) Logo

The stock of Acasti Pharma Inc – Class A (NASDAQ:ACST) registered an increase of 87.61% in short interest. ACST’s total short interest was 549,500 shares in June as published by FINRA. Its up 87.61% from 292,900 shares, reported previously. With 260,500 shares average volume, it will take short sellers 2 days to cover their ACST’s short positions. The short interest to Acasti Pharma Inc – Class A’s float is 5.07%.

The stock decreased 11.58% or $0.093 during the last trading session, reaching $0.7099. About 685,730 shares traded or 173.64% up from the average. Acasti Pharma Inc. (NASDAQ:ACST) has declined 43.65% since June 16, 2017 and is downtrending. It has underperformed by 56.22% the S&P500.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company has market cap of $27.06 million. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. It currently has negative earnings.

More recent Acasti Pharma Inc. (NASDAQ:ACST) news were published by: Nasdaq.com which released: “Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on …” on June 12, 2018. Also Nasdaq.com published the news titled: “Acasti Pharma Appoints Brian Groch as Chief Commercial Officer” on June 04, 2018. Nasdaq.com‘s news article titled: “Acasti Pharma to Present at the XVIII(th) International Symposium on Atherosclerosis” with publication date: June 06, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: